Clinical Trial

Effect of Esketamine on Postoperative Depression、Gut Microbiota、Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI)

Study acronym: ESPOD-BI
Unknown Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated July 22, 2024 (before its estimated October 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective, randomized, controlled (randomized, parallel group, concealed allocation), double-blinded trial. All depression patients undergoing breast cancer operation will be randomized 1:1 to the treatment intervention with general anesthesia as an adjunct to esketamine or saline. The objective of the trial is to evaluate the postoperative depression、gut microbiota、bispectral index data of patients undergoing breast cancer operation with esketamine or saline.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT04303325
Lead Sponsor China Medical University, China
Conditions Depression
Enrollment 72 participants
Start Date 2021-10-08
Primary Completion 2024-10-30 (estimated)
Study Completion 2024-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-22